Merrill reinstates PerkinElmer at neutral

Merrill Lynch analyst Jonathan Groberg reinstated coverage of PerkinElmer Inc. at a neutral rating. While the company participates, and is a market leader, in some interesting high-growth markets; the analyst believes shares are fairly valued given the stock's recent run; the company's operating history and product portfolio; and Groberg's growth expectations. Shares of the Wellesley, Mass., pharmaceutical products company were down 21 cents, or 0.97%, at $21.49. (NYSE: PKI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.